亚博下载app-安卓版下载

English
Company profile/News
OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cancer
2016/11/17
Signed Agreement with Cell Culture Company (C3) for Manufacturing of Clinical Grade Antibody to Support Planned Clinical Studies
Details  
Cell Culture Company (C3) Deal Targets Pancreatic Cancer
2016/11/10
Chinese BioPharma Awards Minnesota Company Therapeutic Contract
Details  
OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cance
2016/10/31
Signed Agreement with Cell Culture Company (C3) for Manufacturing ofClinical Grade Antibody to Support Planned Clinical Studies EDMONTON, ALBERTA, November 2, 2016 – OncoQuest Inc.(“OncoQuest’), a biopharmaceuticalcompany focused on the development and commercialization of immunotherapeuticproducts for the treatment of cancer, today announces that itsJoint Venture Partner in China, OncoVent Co., Ltd. (“OncoVent”) has launchedits clinical development program for Anti-MUC1 MAb AR20.5 for the treatment ofpancreatic cancer. Based on the previous clinical experience and recentlyannounced positi…
Details  
Quest PharmaTech's Subsidiary, OncoQuest, Signs Agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. to Build Oncovent in China
2016/09/12
China-based global pharmaceutical focusing on the development of combination immunotherapy for the China market
Details  
View more+